By Associate Professor Jane Ellen Carland

Journal articles

Kamel B; Williams KM; Graham GG; Norris RLG; Stocker SL; Carland JE; Pile KD; Day RO, 2019, 'Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection', Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121764

Day RO; Lau W; Stocker SL; Aung E; Coleshill MJ; Schulz M; Bechara J; Carland JE; Graham GG; Williams KM; McLachlan AJ, 2019, 'Management of gout in older people', Journal of Pharmacy Practice and Research, 49, pp. 90 - 97, http://dx.doi.org/10.1002/jppr.1511

Shingde RV; Graham GG; Reuter SE; Carland JE; Day RO; Stocker SL, 2019, 'Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function.', Ther Drug Monit, 41, pp. 726 - 731, http://dx.doi.org/10.1097/FTD.0000000000000690

Chan JOS; Baysari MT; Carland JE; Sandaradura I; Moran M; Day RO, 2018, 'Barriers and facilitators of appropriate vancomycin use: prescribing context is key', European Journal of Clinical Pharmacology, 74, pp. 1523 - 1529, http://dx.doi.org/10.1007/s00228-018-2525-2

Carland JE; Smith FC; Day RO, 2018, 'Lactic Acidosis, Metformin Use, and Dose-Response Association', JAMA Internal Medicine, 178, pp. 1428 - 1429, http://dx.doi.org/10.1001/jamainternmed.2018.4448

Roberts DM; Sevastos J; Carland JE; Stocker SL; Lea-Henry TN, 2018, 'Clinical pharmacokinetics in kidney disease application to rational design of dosing regimens', Clinical Journal of the American Society of Nephrology, 13, pp. 1254 - 1263, http://dx.doi.org/10.2215/CJN.05150418

Lea-Henry TN; Carland JE; Stocker SL; Sevastos J; Roberts DM, 2018, 'Clinical pharmacokinetics in kidney disease: Fundamental principles', Clinical Journal of the American Society of Nephrology, 13, pp. 1085 - 1095, http://dx.doi.org/10.2215/CJN.00340118

Nguyen AD; Frensham LJ; Baysari MT; Carland JE; Day RO, 2018, 'Patients' use of mobile health applications: What general practitioners think', Family Practice, 36, pp. 214 - 218, http://dx.doi.org/10.1093/fampra/cmy052

Carland JE; Thomas M; Mostyn SN; Subramanian N; O'Mara ML; Ryan RM; Vandenberg RJ, 2018, 'Molecular Determinants for Substrate Interactions with the Glycine Transporter GlyT2', ACS Chemical Neuroscience, 9, pp. 603 - 614, http://dx.doi.org/10.1021/acschemneuro.7b00407

Day R; Kamel B; Graham GG; Williams KM; Stocker SL; Carland JE; Pile KD; Mcguigan LE; Portek IJ; Mcgill NW, 2018, 'A Multicentre Open-Label Pharmacokinetic-Pharmacodynamic Study of Febuxostat in Patients with Chronic Gout', Proceedings for Annual Meeting of The Japanese Pharmacological Society, WCP2018, http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_po1-11-12

Mostyn SN; Carland JE; Shimmon S; Ryan RM; Rawling T; Vandenberg RJ, 2017, 'Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2', ACS Chemical Neuroscience, 8, pp. 1949 - 1959, http://dx.doi.org/10.1021/acschemneuro.7b00105

Day RO; Kannangara DRW; Stocker SL; Carland JE; Williams KM; Graham GG, 2017, 'Allopurinol: insights from studies of dose–response relationships', Expert Opinion on Drug Metabolism and Toxicology, 13, pp. 449 - 462, http://dx.doi.org/10.1080/17425255.2017.1269745

Vandenberg RJ; Mostyn SN; Carland JE; Ryan RM, 2016, 'Glycine transporter2 inhibitors: Getting the balance right', Neurochemistry International, 98, pp. 89 - 93, http://dx.doi.org/10.1016/j.neuint.2015.12.007

Subramanian N; Scopelliti AJ; Carland JE; Ryan RM; O'Mara ML; Vandenberg RJ, 2016, 'Correction: Identification of a 3rd Na+ binding site of the glycine transporter, GlyT2', Plos One, 11, http://dx.doi.org/10.1371/journal.pone.0159896

Subramanian N; Scopelitti AJ; Carland JE; Ryan RM; O'Mara ML; Vandenberg RJ, 2016, 'Identification of a 3rd Na+ binding site of the glycine transporter, GlyT2', Plos One, 11, pp. e0157583, http://dx.doi.org/10.1371/journal.pone.0157583

Vandenberg R; Carland J; Edington A; Ryan R, 2015, 'Molecular Basis for Substrate and Inhibitor Interactions with the Glycine Transporter, GlyT2', FASEB JOURNAL, 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361470504039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carland JE; Yamamoto I; Hanrahan JR; Abdel-Halim H; Lewis TM; Absalom N; Chebib M, 2015, 'A Hydrophobic Area of the GABA ρ1 Receptor Containing Phenylalanine 124 Influences Both Receptor Activation and Deactivation', Journal of Molecular Neuroscience, 55, pp. 305 - 313, http://dx.doi.org/10.1007/s12031-014-0322-7

Vandenberg RJ; Ryan RM; Carland JE; Imlach WL; Christie MJ, 2014, 'Glycine transport inhibitors for the treatment of pain', Trends in Pharmacological Sciences, 35, pp. 423 - 430, http://dx.doi.org/10.1016/j.tips.2014.05.006

Carland JE; Handford CA; Ryan RM; Vandenberg RJ, 2014, 'Lipid inhibitors of high affinity glycine transporters: Identification of a novel class of analgesics', Neurochemistry International, 73, pp. 211 - 216, http://dx.doi.org/10.1016/j.neuint.2013.08.012

Carland JE; Cooper MA; Livesey MR; Hales TG; Peters JA; Lambert JJ, 2013, 'Mutagenic analysis of the intracellular portals of the human 5-HT 3A receptor', Journal of Biological Chemistry, 288, pp. 31592 - 31601, http://dx.doi.org/10.1074/jbc.M113.503300

Carland JE; Mansfield RE; Ryan RM; Vandenberg RJ, 2013, 'Oleoyl-L-carnitine inhibits glycine transport by GlyT2', British Journal of Pharmacology, 168, pp. 891 - 902, http://dx.doi.org/10.1111/j.1476-5381.2012.02213.x

Yamamoto I; Absalom N; Carland JE; Doddareddy MR; Gavande N; Johnston GAR; Hanrahan JR; Chebib M, 2012, 'Differentiating enantioselective actions of GABOB: A possible role for threonine 244 in the binding site of GABAc ρ1 receptors', ACS Chemical Neuroscience, 3, pp. 665 - 673, http://dx.doi.org/10.1021/cn3000229

Yamamoto I; Carland JE; Locock K; Gavande N; Absalom N; Hanrahan JR; Allan RD; Johnston GAR; Chebib M, 2012, 'Structurally diverse GABA antagonists interact differently with open and closed conformational states of the ρ1 receptor', ACS Chemical Neuroscience, 3, pp. 293 - 301, http://dx.doi.org/10.1021/cn200121r

Peters JA; Cooper MA; Carland JE; Livesey MR; Hales TG; Lambert JJ, 2010, 'Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors', Journal of Physiology, 588, pp. 587 - 596, http://dx.doi.org/10.1113/jphysiol.2009.183137

Sugiharto S; Carland JE; Lewis TM; Moorhouse AJ; Barry PH, 2010, 'External divalent cations increase anion-cation permeability ratio in glycine receptor channels', Pflugers Archiv - European Journal of Physiology, 460, pp. 131 - 152, http://dx.doi.org/10.1007/s00424-010-0792-6

Carland JE; cooper MA; Sugiharto S; Jeong H; Lewis TM; Barry PH; Peters JA; Lambert J; Moorhouse AJ, 2009, 'Characterization of the effects of charged residues in the intracellular loop on ion permeation in α1 glycine receptor channels', The Journal of Biological Chemistry, 284, pp. 2023 - 2030, http://dx.doi.org/10.1074/jbc.M806618200

Carland JE; Johnston G; Chebib M, 2008, 'Relative impact of residues at the intracellular and extracellular ends of the human GABA(C) rho 1 receptor M2 domain on picrotoxinin activity', European Journal of Pharmacology, 580, pp. 27 - 35

Livesey M; Cooper M; Deeb T; Carland JE; kozuska J; Hales T; Lambert J; Peters J, 2008, 'Structural determinants of Ca2+ permeability and conduction in the human 5-hydroxytryptamine type 3A receptor', The Journal of Biological Chemistry, 283, pp. 19301 - 19313

Deeb T; Carland JE; Cooper MA; Livesey M; Lambert J; Peters J; Hales T, 2007, 'Dynamic modification of a mutant cytoplasmic residue modulates the conductance of the human 5-HT3A receptor', The Journal of Biological Chemistry, 282, pp. 6172 - 6182, http://dx.doi.org/10.1074/jbc.M607698200

Hales T; Dunlop JI; Deeb T; Carland JE; Kelley SP; Lambert J; Peters J, 2006, 'Common determinants of single channel conductance within the large cytoplasmic loop of 5-HT3 and á4â2 nicotinic acetylcholine receptors', The Journal of Biological Chemistry, 281, pp. 8062 - 8071, http://dx.doi.org/10.1074/jbc.M513222200

Peters J; Carland JE; Cooper MA; Livesey M; Deeb T; Hales T; Lambert J, 2006, 'Novel structural determinants of single channel conductance in nicotinic acetylcholine and 5-hydroxytryptamine type-3 receptors', Biochemical Society Transactions, 34, pp. 882 - 886, http://www.biochemsoctrans.org/bst/034/0882/0340882.pdf

Barker D; Lin DH-S; Carland JE; Chu CP-Y; Chebib M; Brimble MA; Savage GP; McLeod MD, 2005, 'Methyllycaconitine analogues have mixed antagonist effects at nicotinic acetylcholine receptors', Bioorganic and Medicinal Chemistry, 13, pp. 4565 - 4575, http://dx.doi.org/10.1016/j.bmc.2005.04.054

Carland JE; Moorhouse AJ; Barry PH; Johnston G; Chebib M, 2004, 'Charged residues at the 2 ` position of human GABA(c) rho 1 receptorsinvert ion selectivity and influence open state probability', The Journal of Biological Chemistry, 279, pp. 54153 - 54160

Carland JE; Moore AM; Hanrahan JR; Mewett KN; Duke RK; Johnston G; Chebib M, 2004, 'Mutations of the 2' proline in the M2 domain of the human GABAC ĉ1 subunit alter agonist responses', Neuropharmacology, 46, pp. 770 - 781, http://dx.doi.org/10.1016/j.neuropharm.2003.11.027

Conference Papers

Barry PH; Sugiharto S; Carland JE; Lewis TM; Schofield PR; Moorhouse AJ, 2008, 'External divalent ions increase anion-cation permeability in glycine receptor channels – consideration of ion activities, surface charge and conductance measurements', in Proceedings of the Australian Physiological and Pharmacological Society, presented at Australian Physiological and Pharmacological Society Conference 2008

Conference Posters

Jones N; Carland J; Daniel B; Finch A; Hanna G; Kumar N, 2023, 'A novel practical class using crickets to demonstrate the pharmacological actions of drugs for third year neuropharmacology students', presented at ANS, 04 December 2023 - 07 December 2023

Paul H; Nguyen Y; Jazayeri F; Preisz P; Huber J; Brett J; Carland J, 2023, 'Patient’s experience of a psychiatric, alcohol and non-prescription drug assessment (PANDA) unit', Sydney, presented at ASCEPT, Sydney, 20 November 2023 - 23 November 2023

Chowdhury G; Carland J; Stocker S; MacDonald P; Greenfield J; Day R, 2022, 'The trends and opinions of Australian clinicians on the use of antihyperglycemic agents in heart failure patients', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2022 - 29 November 2019

Kirubakaran R; Uster D; Hennig S; Carland J; Day R; Wicha S; Stocker S, 2021, 'Matters close to the heart: adaptation of a tacrolimus model to inform therapeutic drug monitoring using the PRIOR approach', Virtual, presented at American Conference on Pharmacometrics, Virtual, 08 November 2021 - 12 November 2021

Kirubakaran R; Uster D; Hennig S; Carland J; Day R; Wicha S; Stocker S, 2021, 'Matters close to the heart: adaptation of a tacrolimus model to inform therapeutic drug monitoring using the PRIOR approach', Virtual, presented at IATDMCT, Virtual, 19 September 2021 - 22 September 2021

Kirubakaran R; Uster D; Hennig S; Carland J; Day R; Stocker S, 2021, 'Matters close to the heart: adaptation of a tacrolimus model to inform therapeutic drug monitoring using the PRIOR approach', Virtual, presented at Population Approach Group Europe, Virtual, 02 September 2021 - 07 September 2021

Singh R; Kirubakaran R; Day R; Carland J; Stocker S, 2020, 'Predictive performance of population pharmacokinetic models for tacrolimus in lung transplant recipients', Virtual, presented at ASCEPT, Virtual, 29 November 2020 - 02 December 2020

Shen C; Baysari M; Watters E; Debono D; Day R; Carland J; Stocker S, 2020, 'A step forward in patient safety - understanding barriers to correct intravenous medication administrations', Virtual, presented at ASCEPT, Virtual, 29 November 2020 - 02 December 2020

Kirubakaran R; Hennig S; Carland J; Day R; Stocker S, 2020, 'External evaluation of population pharmacokinetic models of tacrolimus in adult heart transplant recipients', presented at Pharmacometrics Japan, 22 January 2020 - 23 January 2020

Roydhouse S; Carland J; Baysari M; Debono D; Day R, 2019, 'Accuracy of documented administration times for intravenous antimicrobial drugs', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019

Yager R; Stocker S; Day R; Baysari M; Taylor N; Carland J, 2019, 'Barriers and facilitators to user acceptance of a pilot therapeutic drug monitoring advisory service for vancomycin', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019

Kirubakaran R; Hennig S; Maslen B; Carland J; Day R; Stocker S, 2019, 'External evaluation of published population pharmacokinetic models of tacrolimus in adult heart transplant recipients', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019

Kirubakaran R; Hennig S; Stocker S; Day R; Carland J, 2019, 'Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019

Carland J; Stocker S; Elhage T; Marriott D; Baysari M; Day R, 2019, 'Designing a therapeutic drug monitoring (TDM) advisory service for vancomycin: identifying barriers and facilitators to service implementation', Darwin, Australia, presented at ASID, Darwin, Australia, 16 May 2019 - 18 May 2019

Shingde R; Graham G; Reuter S; Carland J; Williams K; Day R; Stocker S, 2019, 'Predictive performance of a commercial Bayesian forecasting program in estimating vancomycin drug exposure', Washington DC, USA, presented at American Society for Clinical Pharmacology and Therapeutics, Washington DC, USA, 14 March 2019 - 16 March 2019

Back to profile page